

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

Brilliant Violet 785(TM) anti-mouse/human CD44

RRID:AB_2571953

Type: Antibody

Proper Citation

BioLegend Cat# 103059, RRID:AB_2571953

Antibody Information

URL: http://antibodyregistry.org/AB_2571953

Proper Citation: BioLegend Cat# 103059, RRID:AB_2571953

Target Antigen: CD44

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse/human CD44

Description: This monoclonal targets CD44

Target Organism: mouse, human

Clone ID: Clone IM7

Antibody ID: AB_2571953

Vendor: BioLegend

Catalog Number: 103059

Alternative Catalog Numbers: 103041

Record Creation Time: 20250820T041303+0000

Record Last Update: 20250820T182153+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse/human CD44.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse/human CD44.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 51 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Mariancini A, et al. (2026) IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma. Cancer immunology research, 14(5), 751.

Hoyt-Miggelbrink AM, et al. (2026) Upregulation of TNFR2 Precedes TOX Expression by Exhausted T cells and Restricts Antitumor and Antiviral Immunity. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(4), 782.

Lam JY, et al. (2026) Nasal RNA-scaffold-protein vaccine protects mice from human H5N1 clade 2.3.4.4b virus lethal infection and safeguards against vaccine-unmatched viruses. EBioMedicine, 126, 106228.

Bosma DMT, et al. (2026) Requirements for development of T helper 1 and T follicular helper cells from a common precursor. Cell reports, 45(5), 117296.

Miakicheva S, et al. (2026) LEF1 and niche factors determine T cell stemness across chronic diseases. Cell, 189(14), 4325.

Linger ME, et al. (2025) Bivalent mRNA vaccine booster enhances immunity against XBB.1.5 more effectively than breakthrough infection in K18-hACE2 mice. iScience, 28(10), 113479.

Alicea Pauneto CDM, et al. (2025) Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. Immunity.

Zeng Q, et al. (2025) Gut microbiota-driven pathogenic Th17 cells mediated autoimmune epididymo-orchitis in a mouse model of colitis. iScience, 28(5), 112508.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. Immunity, 58(7), 1670.

Chen KY, et al. (2025) Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodes. Cell, 188(4), 1019.

Ganapathi Sankaran D, et al. (2025) Gene-regulatory programs that specify age-related differences during thymocyte development. *Cell reports*, 44(7), 115903.

Cole AC, et al. (2025) Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity. *Cancer cell*, 43(9), 1697.

Li H, et al. (2025) T cell-intrinsic cGAS-CTCF regulation maintains regulatory T cell development and function. *Cell reports*, 44(10), 116302.

Galvez-Cancino F, et al. (2025) Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. *Immunity*, 58(5), 1236.

Scott MC, et al. (2025) Deep profiling deconstructs features associated with memory CD8+ T cell tissue residence. *Immunity*, 58(1), 162.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. *Cell*, 187(16), 4336.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. *Immunity*, 57(7), 1514.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. *Cancer cell*, 42(6), 1032.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. *Cancer cell*.

Waibl Polania J, et al. (2024) Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. *Immunity*.